Literature DB >> 20978378

Novel adenovirus vector-based vaccines for HIV-1.

Dan H Barouch1.   

Abstract

PURPOSE OF REVIEW: Recombinant adenovirus (rAd) vectors have emerged as promising vaccine platform technologies due to their capacity to elicit potent humoral and cellular immune responses to encoded antigens. These vectors are being explored as potential vaccine candidates for a variety of pathogens. This review summarizes current efforts to develop rAd vector-based vaccines for HIV-1. RECENT
FINDINGS: In the phase 2b Step study, rAd5 vectors expressing clade B HIV-1 Gag, Pol, and Nef antigens failed to afford protection and may have resulted in increased HIV-1 acquisition in certain subgroups. Recent studies have explored the potential reasons for this failure and the utility of novel rAd vectors derived from non-Ad5 serotypes.
SUMMARY: Current areas of active investigation include the development of alternative serotype rAd vectors, the incorporation of rAd vectors into heterologous vector prime-boost regimens, and the use of rAd vectors to express novel HIV-1 antigens. These HIV-1 vaccine candidates will be evaluated in clinical trials over the next several years.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20978378      PMCID: PMC2967414          DOI: 10.1097/COH.0b013e32833cfe4c

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  39 in total

1.  Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Authors:  Ronald Vogels; David Zuijdgeest; Richard van Rijnsoever; Eric Hartkoorn; Irma Damen; Marie-Pierre de Béthune; Stefan Kostense; Germaine Penders; Niels Helmus; Wouter Koudstaal; Marco Cecchini; Antoinette Wetterwald; Mieke Sprangers; Angelique Lemckert; Olga Ophorst; Björn Koel; Michelle van Meerendonk; Paul Quax; Laura Panitti; Jos Grimbergen; Abraham Bout; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

2.  Replication-defective vector based on a chimpanzee adenovirus.

Authors:  S F Farina; G P Gao; Z Q Xiang; J J Rux; R M Burnett; M R Alvira; J Marsh; H C Ertl; J M Wilson
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.

Authors:  Dan H Barouch; Jennifer Kunstman; Marcelo J Kuroda; Jörn E Schmitz; Sampa Santra; Fred W Peyerl; Georgia R Krivulka; Kristin Beaudry; Michelle A Lifton; Darci A Gorgone; David C Montefiori; Mark G Lewis; Steven M Wolinsky; Norman L Letvin
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

4.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

5.  A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.

Authors:  Julie C Fitzgerald; Guang-Ping Gao; Arturo Reyes-Sandoval; George N Pavlakis; Zhi Q Xiang; Anthony P Wlazlo; Wynetta Giles-Davis; James M Wilson; Hildegund C J Ertl
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

6.  Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors.

Authors:  Danilo R Casimiro; Andrew J Bett; Tong-ming Fu; Mary-Ellen Davies; Aimin Tang; Keith A Wilson; Minchun Chen; Romnie Long; Troy McKelvey; Michael Chastain; Sanjay Gurunathan; Jim Tartaglia; Emilio A Emini; John Shiver
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

7.  Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination.

Authors:  Wing-Pui Kong; Lan Wu; Timothy C Wallstrom; Will Fischer; Zhi-Yong Yang; Sung-Youl Ko; Norman L Letvin; Barton F Haynes; Beatrice H Hahn; Bette Korber; Gary J Nabel
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

8.  Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.

Authors:  Dan H Barouch; Maria G Pau; Jerome H H V Custers; Wouter Koudstaal; Stefan Kostense; Menzo J E Havenga; Diana M Truitt; Shawn M Sumida; Michael G Kishko; Janelle C Arthur; Birgit Korioth-Schmitz; Michael H Newberg; Darci A Gorgone; Michelle A Lifton; Dennis L Panicali; Gary J Nabel; Norman L Letvin; Jaap Goudsmit
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

Review 9.  Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors.

Authors:  John W Shiver; Emilio A Emini
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739

10.  Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys.

Authors:  Dan H Barouch; Jennifer Kunstman; Jennifer Glowczwskie; Kevin J Kunstman; Michael A Egan; Fred W Peyerl; Sampa Santra; Marcelo J Kuroda; Jörn E Schmitz; Kristin Beaudry; Georgia R Krivulka; Michelle A Lifton; Darci A Gorgone; Steven M Wolinsky; Norman L Letvin
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

View more
  67 in total

1.  Genetic immunization in the lung induces potent local and systemic immune responses.

Authors:  Kaimei Song; Diane L Bolton; Chih-Jen Wei; Robert L Wilson; Jeremy V Camp; Saran Bao; Joseph J Mattapallil; Leonore A Herzenberg; Leonard A Herzenberg; Charla A Andrews; Jerald C Sadoff; Jaap Goudsmit; Maria Grazia Pau; Robert A Seder; Pamela A Kozlowski; Gary J Nabel; Mario Roederer; Srinivas S Rao
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-06       Impact factor: 11.205

2.  Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.

Authors:  Nicole Frahm; Allan C DeCamp; David P Friedrich; Donald K Carter; Olivier D Defawe; James G Kublin; Danilo R Casimiro; Ann Duerr; Michael N Robertson; Susan P Buchbinder; Yunda Huang; Gregory A Spies; Stephen C De Rosa; M Juliana McElrath
Journal:  J Clin Invest       Date:  2011-12-27       Impact factor: 14.808

3.  The ideal vaccine: until death do us part.

Authors:  Hildegund C J Ertl
Journal:  Mol Ther       Date:  2011-05       Impact factor: 11.454

Review 4.  State-of-the-art gene-based therapies: the road ahead.

Authors:  Mark A Kay
Journal:  Nat Rev Genet       Date:  2011-04-06       Impact factor: 53.242

5.  Novel HIV vaccine strategies: overview and perspective.

Authors:  Yehuda Z Cohen; Raphael Dolin
Journal:  Ther Adv Vaccines       Date:  2013-09

6.  Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.

Authors:  Glenda E Gray; Zoe Moodie; Barbara Metch; Peter B Gilbert; Linda-Gail Bekker; Gavin Churchyard; Maphoshane Nchabeleng; Koleka Mlisana; Fatima Laher; Surita Roux; Kathryn Mngadi; Craig Innes; Matsontso Mathebula; Mary Allen; M Julie McElrath; Michael Robertson; James Kublin; Lawrence Corey
Journal:  Lancet Infect Dis       Date:  2014-02-20       Impact factor: 25.071

7.  Rare Control of SIVmac239 Infection in a Vaccinated Rhesus Macaque.

Authors:  Mauricio A Martins; Damien C Tully; Young C Shin; Lucas Gonzalez-Nieto; Kim L Weisgrau; David J Bean; Rujuta Gadgil; Martin J Gutman; Aline Domingues; Helen S Maxwell; Diogo M Magnani; Michael Ricciardi; Nuria Pedreño-Lopez; Varian Bailey; Michael A Cruz; Noemia S Lima; Myrna C Bonaldo; John D Altman; Eva Rakasz; Saverio Capuano; Keith A Reimann; Michael Piatak; Jeffrey D Lifson; Ronald C Desrosiers; Todd M Allen; David I Watkins
Journal:  AIDS Res Hum Retroviruses       Date:  2017-06-29       Impact factor: 2.205

Review 8.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

9.  Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.

Authors:  Stephen R Walsh; Zoe Moodie; Andrew J Fiore-Gartland; Cecilia Morgan; Marissa B Wilck; Scott M Hammer; Susan P Buchbinder; Spyros A Kalams; Paul A Goepfert; Mark J Mulligan; Michael C Keefer; Lindsey R Baden; Edith M Swann; Shannon Grant; Hasan Ahmed; Fusheng Li; Tomer Hertz; Steven G Self; David Friedrich; Nicole Frahm; Hua-Xin Liao; David C Montefiori; Georgia D Tomaras; M Juliana McElrath; John Hural; Barney S Graham; Xia Jin
Journal:  J Infect Dis       Date:  2015-10-15       Impact factor: 5.226

10.  Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDS.

Authors:  Monica Vaccari; Rabih Halwani; L Jean Patterson; Adriano Boasso; Jennifer Beal; Elzbieta Tryniszewska; Anna Hryniewicz; David Venzon; Elias K Haddad; Mohamed El-Far; Margherita Rosati; George N Pavlakis; Barbara K Felber; Saleh Al-Muhsen; Marjorie Robert-Guroff; Rafick-Pierre Sekaly; Genoveffa Franchini
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.